EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Combined intravitreal ranibizumab and verteporfin photodynamic therapy versus ranibizumab alone for the treatment of age-related macular degeneration

Rosalia Giustolisi, Nicoletta Fantozzi, Mariateresa Staltari, Jessica Marchiori, Olga Mastrangelo, Roberta Marcucci, Federica Mirra, Paola Mazzotta, Corrado Balacco Gabrieli

Digital Journal of Ophthalmology · 2011

DOI: 10.5693/djo.01.2011.05.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digital Journal of Ophthalmology, 2011. Verfasst von Rosalia Giustolisi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Policlinico Umberto I, Rome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PurposeTo compare same-day combined therapy of photodynamic therapy with verteporfin (PDT-V) and intravitreal ranibizumab versus monotherapy with ranibizumab for the treatment of choroidal neovascularization. MethodsIn this prospective study, the total number of eyes were randomized into two groups: in the first, treatment consisted of a combined therapy of PDT-V and ranibizumab 0.5 mg on the same day; in the second, ranibizumab 0.5 mg in 3 monthly injections. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) on optical coherence tomography (OCT) were recorded before and 6 months after treatment. ResultsA total of 47 eyes of 47 subjects were enrolled in the study. In the combined-therapy group (group 1), the mean baseline BCVA ± standard deviation (SD) was 32.65 ± 11.09 letters (Snellen equivalent, 20/59); in the ranibizumab-alone group (group 2), 29.13 ± 9.03 letters (20/70). At 6 months’ follow-up, in group 1 the mean baseline BCVA was 39.06 ± 10.12 letters (20/42); in group 2, 33.87 ± 12.06 letters (20/57). Improvement was significant in both group 1 (P = 0.03) and group 2 (P = 0.002). In group 1, the mean CMT at baseline ± SD was 315 ± 95.49 μm; in group 2, 306.33 ± 71.61 μm. At 6 months’ follow-up, in group 1 it was 202 ± 52.02 μm; in group 2, 226 ± 65.58 μm. Reduction was significant in both group 1 (P = 0.0007) and group 2 (P = 0.00001). After 6-months, the rate of retreated eyes was 29.4% in group 1 and 43.3% in group 2. The need for retreatment did not depend on the treatment protocol (P = 0.34). ConclusionsFrom a functional and anatomic point of view, the two treatments showed equivalent efficacy, with fewer retreatments in group 1. No serious adverse events, such as retinal detachment, endophthalmitis, or ocular hypertension occurred in either group.

Autor:innen und Institutionen

  • Department of Ophthalmology, Policlinico Umberto I, Rome.

Zitieren

APA

Giustolisi, R., Fantozzi, N., Staltari, M., Marchiori, J., Mastrangelo, O., Marcucci, R., Mirra, F., Mazzotta, P., & Gabrieli, C. B. (2011). Combined intravitreal ranibizumab and verteporfin photodynamic therapy versus ranibizumab alone for the treatment of age-related macular degeneration. Digital Journal of Ophthalmology. https://doi.org/10.5693/djo.01.2011.05.003

Vancouver

Giustolisi R, Fantozzi N, Staltari M, Marchiori J, Mastrangelo O, Marcucci R, et al. Combined intravitreal ranibizumab and verteporfin photodynamic therapy versus ranibizumab alone for the treatment of age-related macular degeneration. Digital Journal of Ophthalmology. 2011. doi:10.5693/djo.01.2011.05.003

BibTeX
@article{Giustolisi2011,
  author = {Giustolisi, Rosalia and Fantozzi, Nicoletta and Staltari, Mariateresa and Marchiori, Jessica and Mastrangelo, Olga and Marcucci, Roberta and Mirra, Federica and Mazzotta, Paola and Gabrieli, Corrado Balacco},
  title = {Combined intravitreal ranibizumab and verteporfin photodynamic therapy versus ranibizumab alone for the treatment of age-related macular degeneration},
  journal = {Digital Journal of Ophthalmology},
  year = {2011},
  doi = {10.5693/djo.01.2011.05.003}
}
Kostenlos starten →